Companies expanding their biologics portfolios represent a $5 billion market opportunity by 2026, according to a Sept. 9 news release. In recent months companies including Vericel, LifeNet Health and SurGenTec made advances with their spine and orthopedic biologic portfolios, earning FDA nods.
Major players mentioned in the report include Arthrex, Alphatec and Zimmer Biomet.
The spine device market is also expected to grow due to factors such as rising investments in 3D printed technology, demand for motion preserving devices and adoption of minimally invasive procedures, according to the report.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
